| Drug Name |
Cenobamate |
| Drug ID |
BADD_D02542 |
| Description |
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.[L10653]
Cenobamate was granted FDA approval on 21 November 2019.[L10653] |
| Indications and Usage |
Cenobamate is indicated for the treatment of partial onset seizures in adults.[L10653] |
| Marketing Status |
approved; investigational |
| ATC Code |
N03AX25 |
| DrugBank ID |
DB06119
|
| KEGG ID |
D11150
|
| MeSH ID |
C000654784
|
| PubChem ID |
11962412
|
| TTD Drug ID |
DU8CF6
|
| NDC Product Code |
71699-150; 71699-200; 71699-050; 71699-999; 71699-100; 71699-203; 71699-104; 74436-0223; 71699-103; 71699-202; 71699-201 |
| UNII |
P85X70RZWS
|
| Synonyms |
Cenobamate | 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)- | carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl ester | XCOPRI | YKP3089 | YKP-3089 |
